![](/wp-content/themes/yootheme/cache/40/alabama-402c11b5.jpeg)
Local Cdiff information for Alabama
Alabama
Learn about C. diff providers, regulation, clinical trials, and advocacy efforts in Alabama.
Local Cdiff information for Alabama
Alabama
Learn about C. diff providers, regulation, clinical trials, and advocacy efforts in Alabama.
![](/wp-content/themes/yootheme/cache/40/alabama-402c11b5.jpeg)
Providers
Dr. Joseph Brasco MD
Digestive Disease Center Huntsville Hospital
1100 S Jackson Hwy, Suite 100
Sheffield, 35660
(256) 314-2550
FMT Provider: Yes
Regulation
C. diff Infections
Total Reported Cases: 1,077
Hospital Onset: Not reported:
Community Onset: Not reported
Related Deaths: Not reported
Available Reports
State Reporting Laws
Data Submission Required: No
Data Publicly Available: No
Data Validate: No
Facility-specific Data Publicly Reported: No
LTC Facility Submission Required: No
LTC Facility Data Publicly Reported: No
Law/Regulation: Alabama Administrative Code
State Contact
Nadine Crawford
HAI Coordinator, Infection Control Officer
Alabama Department of Public Health
Division of Epidemiology Bureau of Communicable Disease
201 Monroe Street, Suite 1460
Montgomery, 36104
(334) 206-5932
(334) 206-5967
CLINICAL TRIALS
RESTORATiVE303
Official Title: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection
Trial No. NCT06237452
Type: Interventional
Recruitment: Recruiting
Sponsor: Vedanta Biosciences, Inc
Contact: Mary Garfield
Trial No. NCT06237452
Type: Interventional
Recruitment: Recruiting
Sponsor: Vedanta Biosciences, Inc
Contact: Mary Garfield
Gender: All
Age: 12 Years and older
Vedanta Biosciences has teamed up with Science37 to provide a site-less, decentralized approach. This means the study can be done remotely and the product comes to you, in your home. This allows applicants who are not near a study site or unable to travel to participate and receive treatment. You can sign up for the decentralized study here.
AZD5148
Official Title: A Phase I Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD5148 in Healthy Adults
Trial No. NCT06469151
Type: Interventional
Recruitment: Recruiting
Sponsor: AstraZeneca
Contact: AstraZeneca Clinical Study Information Center
Trial No. NCT06469151
Type: Interventional
Recruitment: Recruiting
Sponsor: AstraZeneca
Contact: AstraZeneca Clinical Study Information Center
Gender: All
Age: 18 years to 65 years